{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cervical+Cancer&page=11", "query": { "condition": "Neuroendocrine Cervical Cancer", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 401, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cervical+Cancer&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cervical+Cancer&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T09:49:16.752Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05577182", "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCA32459-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2023-01-05", "completion_date": "2025-10-13", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05577182" }, { "nct_id": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Non-small Cell Lung Cancer", "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Renal Cell Carcinoma", "Esophageal Adenocarcinoma", "Nasopharyngeal Carcinoma", "Oropharyngeal Carcinoma" ], "interventions": [ { "name": "INBRX-105 - PDL1x41BB antibody", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2019-01-30", "completion_date": "2024-10-03", "has_results": false, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03809624" }, { "nct_id": "NCT00358956", "title": "A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "ZD6474 (vandetanib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2006-08", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 2, "location_summary": "Little Rock, Arkansas • Boston, Massachusetts", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358956" }, { "nct_id": "NCT03160274", "title": "Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pheochromocytoma", "Paraganglioma", "Inherited Cancer Syndrome", "Associated Conditions", "Kidney Neoplasms", "Bone Cancer", "Thyroid Neoplasms", "Other Cancer" ], "interventions": [ { "name": "Genetic screening", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2000, "start_date": "2005-10-19", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03160274" }, { "nct_id": "NCT00423254", "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian", "Melanoma", "Renal", "Prostate", "Colorectal", "Endometrial Carcinoma", "Cervical Carcinoma", "Testicular Cancer", "Thyroid Cancer", "Small Cell Lung Carcinoma", "Mesothelioma", "Breast Carcinoma", "Esophageal Carcinoma", "Gastric Cancer", "Pancreatic Carcinoma", "Neuroendocrine Cancer", "Liver Cancer", "Gallbladder Cancer", "Biliary Tract Cancer", "Anal Carcinoma", "Bone Sarcomas", "Soft Tissue Sarcomas", "Carcinoma of Unknown Origin, Primary" ], "interventions": [ { "name": "PSMA/PRAME", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-02", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 5, "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sparks", "state": "Nevada" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423254" }, { "nct_id": "NCT05913388", "title": "GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "GB1211", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2024-02-29", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05913388" }, { "nct_id": "NCT06168825", "title": "Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Breast Cancer", "Brain Cancer", "Central Nervous System Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gynecologic Cancer", "Head and Neck Cancer", "Gastrointestinal Cancer", "Genitourinary Cancer", "Melanoma", "Blood Cancer", "Lung Cancer", "Acceptance and Commitment Therapy", "Mind-Body Therapies", "Psychosocial Intervention" ], "interventions": [ { "name": "Mind Over Matter (MOM)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2024-01-17", "completion_date": "2024-06-04", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Fairfax, Virginia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06168825" }, { "nct_id": "NCT02487095", "title": "Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small -Cell Lung", "Ovarian Neoplasms", "Small Cell Lung Carcinoma", "Uterine Cervical Neoplasms", "Carcinoma, Neuroendocrine", "Extrapulmonary Small Cell Cancer" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "VX-970 (M6620)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2015-07-30", "completion_date": "2024-12-26", "has_results": true, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02487095" }, { "nct_id": "NCT02178722", "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Microsatellite-instability (MSI) High Colorectal Cancer (CRC)", "Endometrial Cancer", "Head and Neck Cancer", "Hepatocellular Carcinoma (HCC)", "Gastric Cancer", "Lung Cancer", "Lymphoma", "Renal Cell Carcinoma (RCC)", "Ovarian Cancer", "Solid Tumors", "UC (Urothelial Cancer)", "Melanoma", "Bladder Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "MK-3475", "type": "DRUG" }, { "name": "INCB024360", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-07-17", "completion_date": "2020-11-06", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 24, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178722" }, { "nct_id": "NCT02153905", "title": "T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Cervical Cancer", "Renal Cancer", "Melanoma", "Bladder Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2014-07-03", "completion_date": "2018-09-10", "has_results": true, "last_update_posted_date": "2019-06-17", "last_synced_at": "2026-10-19T09:49:16.752Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02153905" } ] }